Olema Pharmaceuticals Shares Enter Oversold Territory
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy OLMA?
Source: NASDAQ.COM
- Oversold Signal: Olema Pharmaceuticals (Ticker: OLMA) saw its RSI drop to 23.4 on Monday, indicating an oversold condition that suggests recent heavy selling may be exhausting, thus providing potential buying opportunities for investors.
- Price Fluctuation: OLMA shares hit a low of $12.99, and with a current trading price of $17.49 compared to its 52-week low of $2.86 and high of $36.2591, there is potential for a rebound that may attract bargain hunters.
- Market Comparison: OLMA's low RSI compared to the S&P 500 ETF's (SPY) current RSI of 36.7 may draw bullish investors' attention, suggesting that there is room for price recovery, which could influence overall market sentiment.
- Investor Strategy: In an oversold condition, investors might consider buying during price recoveries to capitalize on market volatility, especially in the current environment where finding undervalued stocks is becoming a strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OLMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OLMA
Wall Street analysts forecast OLMA stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.760
Low
20.00
Averages
42.00
High
60.00
Current: 15.760
Low
20.00
Averages
42.00
High
60.00
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Olema Pharmaceuticals Stock Plummets Amid Clinical Trial Developments
- Disappointing Clinical Results: Roche's phase 3 study of giredestrant combined with palbociclib failed to show a statistically significant improvement in progression-free survival compared to letrozole, leading to decreased market confidence in Olema and pressuring its stock price.
- Optimistic Progress for Palazestrant: Olema's lead candidate, Palazestrant, is a novel oral estrogen receptor antagonist undergoing various breast cancer trials, and despite challenges, the market remains optimistic about its potential.
- Bearish Technical Indicators: The stock is currently trading 26.2% below its 20-day SMA and 19% below its 100-day SMA, indicating a bearish trend in the short term, prompting caution among investors.
- Price Movement Analysis: Olema shares fell 2.54% to $15.36 on Wednesday, and while the stock has surged 294.05% over the past year, it is now closer to its 52-week lows, reflecting market uncertainty.
See More
Olema Pharmaceuticals and Capital One See High Options Trading Volume
- Olema Options Volume: Olema Pharmaceuticals Inc saw options trading volume of 6,864 contracts, equating to approximately 686,400 shares, which represents about 55.1% of its average daily trading volume of 1.2 million shares over the past month, indicating heightened market interest in its future performance.
- High Put Option Activity: Notably, the $14 strike put option expiring on April 17, 2026, has seen 2,044 contracts traded today, representing around 204,400 underlying shares, suggesting increased investor expectations for a price decline.
- Capital One Options Trading: Capital One Financial Corp experienced options trading volume of 27,954 contracts, translating to approximately 2.8 million shares, or about 51.7% of its average daily trading volume of 5.4 million shares over the past month, reflecting market attention on its stock volatility.
- Active Put Option Trading: Particularly, the $220 strike put option expiring on March 20, 2026, has recorded 4,806 contracts traded today, representing about 480,600 underlying shares, indicating a cautious outlook from investors regarding Capital One's future performance.
See More
DJS Law Group Investigates Olema Pharmaceuticals Investor Claims
- Investigation Background: DJS Law Group has announced an investigation into claims on behalf of investors of Olema Pharmaceuticals (NASDAQ:OLMA), focusing on potential violations of securities laws, including misleading statements or failure to disclose critical information.
- Market Reaction: Following a report from Investor's Business Daily on March 9, 2026, regarding the failure of a Roche trial for an oral breast cancer medication, Olema's shares fell by over 19.6% in morning trading, indicating significant investor concern.
- Analyst Insights: Analyst Matthew Biegler highlighted that the Roche trial results negatively impact the thesis that oral SERDs can succeed in front-line breast cancer treatment, raising further doubts about Olema's competitive position in the market.
- Legal Service Commitment: DJS Law Group is dedicated to enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation, aiming to provide high-value legal services to its clients.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Olema Pharmaceuticals Shares Enter Oversold Territory
- Oversold Signal: Olema Pharmaceuticals (Ticker: OLMA) saw its RSI drop to 23.4 on Monday, indicating an oversold condition that suggests recent heavy selling may be exhausting, thus providing potential buying opportunities for investors.
- Price Fluctuation: OLMA shares hit a low of $12.99, and with a current trading price of $17.49 compared to its 52-week low of $2.86 and high of $36.2591, there is potential for a rebound that may attract bargain hunters.
- Market Comparison: OLMA's low RSI compared to the S&P 500 ETF's (SPY) current RSI of 36.7 may draw bullish investors' attention, suggesting that there is room for price recovery, which could influence overall market sentiment.
- Investor Strategy: In an oversold condition, investors might consider buying during price recoveries to capitalize on market volatility, especially in the current environment where finding undervalued stocks is becoming a strategy.
See More
Olema Pharmaceuticals Stock Declines Following Clinical Trial Setback
- Clinical Trial Setback: Olema Pharmaceuticals' phase 3 study of giredestrant combined with palbociclib failed to achieve a statistically significant improvement in progression-free survival compared to letrozole plus palbociclib, resulting in bearish pressure on the stock as investors express concerns over product prospects.
- Price Trend Analysis: Currently trading at $17.14, Olema's stock is 26.2% below its 20-day simple moving average and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term, prompting investors to monitor shifts in market sentiment.
- Long-term Performance vs. Current Positioning: Despite a remarkable 294.05% increase in share price over the past 12 months, the stock is now closer to its 52-week lows, suggesting a weakening market confidence in future growth and potential risks of a pullback.
- Analyst Ratings and Price Targets: Despite facing short-term pressures, Olema's stock retains a Buy rating with an average price target of $37.33, reflecting analysts' confidence in its long-term potential, especially as several firms have recently raised their price targets.
See More
Olema Pharmaceuticals Stock Plummets Amid Clinical Trial Developments
- Disappointing Clinical Results: Roche's phase 3 study of giredestrant combined with palbociclib failed to show a statistically significant improvement in progression-free survival compared to letrozole, leading to decreased market confidence in Olema and pressuring its stock price.
- Optimistic Progress for Palazestrant: Olema's lead candidate, Palazestrant, is a novel oral estrogen receptor antagonist undergoing various breast cancer trials, and despite challenges, the market remains optimistic about its potential.
- Bearish Technical Indicators: The stock is currently trading 26.2% below its 20-day SMA and 19% below its 100-day SMA, indicating a bearish trend in the short term, prompting caution among investors.
- Price Movement Analysis: Olema shares fell 2.54% to $15.36 on Wednesday, and while the stock has surged 294.05% over the past year, it is now closer to its 52-week lows, reflecting market uncertainty.
See More
Olema Pharmaceuticals and Capital One See High Options Trading Volume
- Olema Options Volume: Olema Pharmaceuticals Inc saw options trading volume of 6,864 contracts, equating to approximately 686,400 shares, which represents about 55.1% of its average daily trading volume of 1.2 million shares over the past month, indicating heightened market interest in its future performance.
- High Put Option Activity: Notably, the $14 strike put option expiring on April 17, 2026, has seen 2,044 contracts traded today, representing around 204,400 underlying shares, suggesting increased investor expectations for a price decline.
- Capital One Options Trading: Capital One Financial Corp experienced options trading volume of 27,954 contracts, translating to approximately 2.8 million shares, or about 51.7% of its average daily trading volume of 5.4 million shares over the past month, reflecting market attention on its stock volatility.
- Active Put Option Trading: Particularly, the $220 strike put option expiring on March 20, 2026, has recorded 4,806 contracts traded today, representing about 480,600 underlying shares, indicating a cautious outlook from investors regarding Capital One's future performance.
See More
DJS Law Group Investigates Olema Pharmaceuticals Investor Claims
- Investigation Background: DJS Law Group has announced an investigation into claims on behalf of investors of Olema Pharmaceuticals (NASDAQ:OLMA), focusing on potential violations of securities laws, including misleading statements or failure to disclose critical information.
- Market Reaction: Following a report from Investor's Business Daily on March 9, 2026, regarding the failure of a Roche trial for an oral breast cancer medication, Olema's shares fell by over 19.6% in morning trading, indicating significant investor concern.
- Analyst Insights: Analyst Matthew Biegler highlighted that the Roche trial results negatively impact the thesis that oral SERDs can succeed in front-line breast cancer treatment, raising further doubts about Olema's competitive position in the market.
- Legal Service Commitment: DJS Law Group is dedicated to enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation, aiming to provide high-value legal services to its clients.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Olema Pharmaceuticals Shares Enter Oversold Territory
- Oversold Signal: Olema Pharmaceuticals (Ticker: OLMA) saw its RSI drop to 23.4 on Monday, indicating an oversold condition that suggests recent heavy selling may be exhausting, thus providing potential buying opportunities for investors.
- Price Fluctuation: OLMA shares hit a low of $12.99, and with a current trading price of $17.49 compared to its 52-week low of $2.86 and high of $36.2591, there is potential for a rebound that may attract bargain hunters.
- Market Comparison: OLMA's low RSI compared to the S&P 500 ETF's (SPY) current RSI of 36.7 may draw bullish investors' attention, suggesting that there is room for price recovery, which could influence overall market sentiment.
- Investor Strategy: In an oversold condition, investors might consider buying during price recoveries to capitalize on market volatility, especially in the current environment where finding undervalued stocks is becoming a strategy.
See More
Olema Pharmaceuticals Stock Declines Following Clinical Trial Setback
- Clinical Trial Setback: Olema Pharmaceuticals' phase 3 study of giredestrant combined with palbociclib failed to achieve a statistically significant improvement in progression-free survival compared to letrozole plus palbociclib, resulting in bearish pressure on the stock as investors express concerns over product prospects.
- Price Trend Analysis: Currently trading at $17.14, Olema's stock is 26.2% below its 20-day simple moving average and 19% below its 100-day SMA, indicating a bearish trend in the short to medium term, prompting investors to monitor shifts in market sentiment.
- Long-term Performance vs. Current Positioning: Despite a remarkable 294.05% increase in share price over the past 12 months, the stock is now closer to its 52-week lows, suggesting a weakening market confidence in future growth and potential risks of a pullback.
- Analyst Ratings and Price Targets: Despite facing short-term pressures, Olema's stock retains a Buy rating with an average price target of $37.33, reflecting analysts' confidence in its long-term potential, especially as several firms have recently raised their price targets.
See More
